GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Forward PE Ratio

Sinovac Biotech (Sinovac Biotech) Forward PE Ratio : 0.00 (As of May. 15, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Forward PE Ratio?

Sinovac Biotech's Forward PE Ratio for today is 0.00.

Sinovac Biotech's PE Ratio without NRI for today is 0.00.

Sinovac Biotech's PE Ratio for today is 0.00.


Sinovac Biotech Forward PE Ratio Historical Data

The historical data trend for Sinovac Biotech's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Forward PE Ratio Chart

Sinovac Biotech Annual Data
Trend
Forward PE Ratio

Sinovac Biotech Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Sinovac Biotech's Forward PE Ratio

For the Biotechnology subindustry, Sinovac Biotech's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinovac Biotech's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's Forward PE Ratio falls into.



Sinovac Biotech Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Sinovac Biotech  (NAS:SVA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Sinovac Biotech Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (Sinovac Biotech) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

Sinovac Amends Shareholder Rights Plan

By Business Wire Business Wire 02-22-2023

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

By Business Wire Business Wire 06-25-2022